INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR KAWASAKI DISEASE (CASE REPORT)
Abstract
Kawasaki disease (KD) is acute vasculitis with an unidentified cause. The prevalence of Kawasaki disease is greater in developed countries or regions, also known as developed areas. Throughout 2021, two cases of complete Kawasaki were identified at Perkebunan Jember Klinik Hospital. Using a Harada score of 3, intravenous immunoglobulin (IGIV) treatment screening was calculated. In general, IGIV is used to reduce the risk of abnormalities/damage to the coronary arteries. The purpose of this study is to identify the diagnostic criteria and indications for administering IGIV to children with Kawasaki disease. Qualitative Method with the case report approach. Patients diagnosed with Kawasaki disease must receive therapy and care based on their symptoms and conditions. Kawasaki disease can be treated with a number of different drugs. IGIV can be delivered to Kawasaki disease patients as a form of treatment. IGIV treatment based on Harada Score. Kawasaki disease is a condition that is rarely recognized by the general public. The resulting conclusions are as follows Complete Kawasaki disease is diagnosed by five days of persistent fever plus 4 of the 5 classic symptoms. Screening with a scoring system is needed in making decisions about giving IGIV.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
An author who publishes in the Jurnal Darma Agung agrees to the following terms:
- Author retains the copyright and grants the journal the right of first publication of the work simultaneously licensed under the Creative Commons Attribution-ShareAlike 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal
- Author is able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book) with the acknowledgement of its initial publication in this journal.
- Author is permitted and encouraged to post his/her work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
